Jardiance Does Not Prolong the QT Interval
No, empagliflozin (Jardiance) does not prolong the QT interval. According to the FDA drug label, a thorough QT study in 30 healthy subjects demonstrated no increase in QTc with either therapeutic (25 mg) or supratherapeutic (200 mg, 8 times the maximum dose) empagliflozin 1.
Evidence from Formal QT Studies
The definitive evidence comes from a randomized, placebo-controlled, active-comparator crossover study that specifically evaluated QT effects:
- No QTc prolongation was observed at either the 25 mg therapeutic dose or the 200 mg supratherapeutic dose
- The study included moxifloxacin as a positive control to confirm assay sensitivity
- This was a properly conducted thorough QT (TQT) study meeting regulatory standards 1
A separate published TQT study confirmed these findings, showing placebo-corrected mean changes from baseline in QTcN of only 0.6 ms (90% CI: -0.7,1.9) for 25 mg and -0.2 ms (-1.4,0.9) for 200 mg—both well below the 10 ms threshold of regulatory concern 2.
Clinical Context: QT-Prolonging Medications
This is particularly relevant when considering the 2023 Canadian Cardiovascular Society guidelines on QT prolongation management. The guidelines emphasize that common QT-prolonging drugs include the "anti's": antibiotics (macrolides, fluoroquinolones), antifungals, antiarrhythmics, antipsychotics/antidepressants, antiemetics, and analgesics 3. Empagliflozin is notably absent from these lists and is not mentioned as a QT-prolonging medication in current guidelines.
Practical Implications
- No ECG monitoring required for QT concerns when initiating empagliflozin
- Safe to use in patients already taking QT-prolonging medications (though standard precautions for those other drugs still apply)
- No contraindication in patients with baseline QT prolongation or long QT syndrome based on QT effects alone
Important Caveat
While empagliflozin doesn't prolong QT, remember that it can cause volume depletion and electrolyte abnormalities (particularly in combination with diuretics). Since hypokalemia and hypomagnesemia can prolong QT, monitor electrolytes appropriately—especially when combining empagliflozin with diuretics or in patients with renal impairment 3.
Emerging Research Suggests Potential Protective Effects
Interestingly, recent animal studies suggest empagliflozin may actually attenuate QT prolongation caused by other drugs. Studies showed empagliflozin significantly reduced sotalol-induced and amitriptyline-induced QT prolongation in rats 4, 5. While these are preclinical findings requiring clinical validation, they suggest empagliflozin's effects on sodium and calcium homeostasis may have anti-arrhythmic properties rather than pro-arrhythmic effects.
Human studies in heart failure patients showed empagliflozin therapy was associated with favorable changes in cardiac repolarization parameters, including decreased QRS-T angle and Tp-e intervals 6. A safety study in end-stage renal disease patients on hemodialysis found empagliflozin actually shortened QRS duration while maintaining stable QT intervals 7.
Bottom line: Empagliflozin is safe from a QT perspective and requires no special ECG monitoring for arrhythmia risk related to QT prolongation.